Company Overview - Arcutis Biotherapeutics, Inc. (ARQT) is part of the Medical group, which consists of 979 companies and is currently ranked 8 in the Zacks Sector Rank [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which includes 489 stocks and is ranked 147 in the Zacks Industry Rank [6] Performance Metrics - Year-to-date, Arcutis Biotherapeutics has gained approximately 6%, while the average return for Medical companies is -7.4%, indicating that ARQT is outperforming its peers [4] - The Zacks Consensus Estimate for ARQT's full-year earnings has increased by 25.7% over the past quarter, reflecting improved analyst sentiment and a stronger earnings outlook [4] Zacks Rank - Arcutis Biotherapeutics currently holds a Zacks Rank of 2 (Buy), which emphasizes its potential for improving earnings outlooks [3] - In comparison, another Medical stock, Tenet Healthcare (THC), has a Zacks Rank of 1 (Strong Buy) and has returned 31.2% year-to-date [5]

Market Overview - The broader indexes have experienced a cooling off after a strong performance in July, with concerns over trade wars and a weaker-than-expected Jobs Report contributing to a pullback [1] - The S&P 500 and Nasdaq have risen over +10% in the last three months, prompting investors to consider defensive positions [2] CVS Health - CVS Health is undergoing a transformation into an innovative pharmacy company, resulting in strong earnings and raised guidance, leading to a stock surge of over +30% this year [3] - CVS stock trades at 10X forward earnings and offers a 4.28% annual dividend yield, indicating strong value [3] - The stock holds a Zacks Rank 2 (Buy) and an overall "A" VGM Zacks Style Scores grade for Value, Growth, and Momentum [4] Johnson & Johnson - Johnson & Johnson is recognized for its reasonable 15.1X forward earnings multiple and a 3.16% annual dividend yield, making it an attractive investment [5] - The company has shown steady growth despite a slowdown, with a diversified business model covering various medical fields [6] - Johnson & Johnson stock is up +15% in 2025, outperforming the S&P 500 and Nasdaq [5] Tenet Healthcare - Tenet Healthcare is rated Zacks Rank 1 (Strong Buy) and is experiencing positive earnings estimate revisions, with expected annual earnings growth of 25% in fiscal 2025 [7][8] - The stock is up +25% year-to-date and trades at 10X forward earnings, indicating strong market performance [8] - FY26 EPS is projected to expand by another 4%, with estimates having increased by 14% in the last 60 days [9]

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section presents the unaudited condensed consolidated financial statements, management's discussion and analysis, and market risk disclosures [Item 1. Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of operations, and cash flows, with accompanying notes [Condensed Consolidated Financial Statements](index=4&type=section&id=Condensed%20Consolidated%20Financial%20Statements) This section provides key financial statements, including balance sheets, statements of operations, and cash flows for the specified periods Condensed Consolidated Balance Sheets (June 30, 2025 vs. December 31, 2024) | Metric | June 30, 2025 ($M) | December 31, 2024 ($M) | | :-------------------------------- | :------------------- | :--------------------- | | Total Assets | 28,699 | 28,936 | | Total Liabilities | 20,397 | 20,389 | | Total Equity | 5,476 | 5,820 | | Cash and Cash Equivalents | 2,625 | 3,019 | | Goodwill | 10,935 | 10,691 | | Long-term debt, net of current portion | 13,091 | 13,081 | Condensed Consolidated Statements of Operations (Three Months Ended June 30, 2025 vs. 2024) | Metric | 3 Months Ended June 30, 2025 ($M) | 3 Months Ended June 30, 2024 ($M) | Change ($M) | Change (%) | | :--------------------------------------- | :-------------------------------- | :-------------------------------- | :---------- | :--------- | | Net operating revenues | 5,271 | 5,108 | 163 | 3.19% | | Operating income | 823 | 761 | 62 | 8.15% | | Net income | 522 | 477 | 45 | 9.43% | | Net income available to common shareholders | 288 | 259 | 29 | 11.20% | | Diluted EPS | 3.14 | 2.64 | 0.50 | 18.94% | Condensed Consolidated Statements of Operations (Six Months Ended June 30, 2025 vs. 2024) | Metric | 6 Months Ended June 30, 2025 ($M) | 6 Months Ended June 30, 2024 ($M) | Change ($M) | Change (%) | | :--------------------------------------- | :-------------------------------- | :-------------------------------- | :---------- | :--------- | | Net operating revenues | 10,494 | 10,476 | 18 | 0.17% | | Operating income | 1,766 | 4,046 | (2,280) | (56.35)% | | Net income | 1,144 | 2,811 | (1,667) | (59.30)% | | Net income available to common shareholders | 694 | 2,410 | (1,716) | (71.20)% | | Diluted EPS | 7.43 | 24.22 | (16.79) | (69.32)% | Condensed Consolidated Statements of Cash Flows (Six Months Ended June 30, 2025 vs. 2024) | Metric | 6 Months Ended June 30, 2025 ($M) | 6 Months Ended June 30, 2024 ($M) | Change ($M) | Change (%) | | :--------------------------------------- | :-------------------------------- | :-------------------------------- | :---------- | :--------- | | Net cash provided by operating activities | 1,751 | 1,333 | 418 | 31.36% | | Net cash provided by (used in) investing activities | (501) | 3,134 | (3,635) | (116.00)% | | Net cash used in financing activities | (1,644) | (2,815) | 1,171 | 41.60% | | Net increase (decrease) in cash and cash equivalents | (394) | 1,652 | (2,046) | (123.85)% | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and supplementary information for the condensed consolidated financial statements [NOTE 1. BASIS OF PRESENTATION](index=10&type=section&id=NOTE%201.%20BASIS%20OF%20PRESENTATION) This note describes Tenet's diversified healthcare services business segments and the basis for financial statement preparation - Tenet is a diversified healthcare services company with Hospital Operations (**49 acute care/specialty hospitals**, **134 outpatient facilities**) and Ambulatory Care (**521 ambulatory surgery centers**, **26 surgical hospitals** via USPI) segments, also operating a Global Business Center (GBC) in the Philippines[20](index=20&type=chunk) Cash and Cash Equivalents | Date | Amount ($M) | | :--------------- | :---------- | | June 30, 2025 | 2,625 | | December 31, 2024 | 3,019 | * **Change:** Decreased by **$394 million** (13.05%) from December 31, 2024 Goodwill Changes (Six Months Ended June 30, 2025 vs. 2024) | Segment | 2025 ($M) | 2024 ($M) | | :------------------ | :-------- | :-------- | | Hospital Operations | 2,697 | 2,869 | | Ambulatory Care | 8,238 | 7,930 | | **Total Goodwill** | **10,935** | **10,799** | - Total other intangible assets, net, decreased to **$1,372 million** at June 30, 2025, from **$1,397 million** at December 31, 2024. Amortization expense for finite-lived intangible assets was **$79 million** for the six months ended June 30, 2025, down from **$89 million** in the prior year period[31](index=31&type=chunk) [NOTE 2. ACCOUNTS RECEIVABLE](index=14&type=section&id=NOTE%202.%20ACCOUNTS%20RECEIVABLE) This note details accounts receivable components, primarily patient accounts, and estimated costs for uninsured and charity patients Accounts Receivable Composition (June 30, 2025 vs. December 31, 2024) | Component | June 30, 2025 ($M) | December 31, 2024 ($M) | | :------------------------------------------ | :------------------- | :--------------------- | | Patient accounts receivable | 2,377 | 2,386 | | Estimated future recoveries | 151 | 144 | | Cost report settlements receivable, net | 5 | 6 | | **Accounts receivable, net** | **2,533** | **2,536** | Estimated Costs for Uninsured and Charity Patients (Six Months Ended June 30, 2025 vs. 2024) | Patient Type | 6 Months Ended June 30, 2025 ($M) | 6 Months Ended June 30, 2024 ($M) | Change ($M) | Change (%) | | :----------------- | :-------------------------------- | :-------------------------------- | :---------- | :--------- | | Uninsured patients | 218 | 271 | (53) | (19.56)% | | Charity care patients | 59 | 46 | 13 | 28.26% | | **Total** | **277** | **317** | **(40)** | **(12.62)%** | [NOTE 3. DISPOSITION OF ASSETS AND LIABILITIES](index=16&type=section&id=NOTE%203.%20DISPOSITION%20OF%20ASSETS%20AND%20LIABILITIES) This note details significant asset dispositions completed in 2024, including hospital sales, which resulted in substantial pre-tax gains - In January 2024, the company completed the sale of three South Carolina hospitals, recognizing a pre-tax gain of **$1.677 billion** in the six months ended June 30, 2024[38](index=38&type=chunk) - In March 2024, the company sold four hospitals in Orange County and Los Angeles County, California, for a pre-tax gain of **$526 million**, and two hospitals in San Luis Obispo County, California, for a pre-tax gain of **$275 million**[44](index=44&type=chunk) - In March 2024, the company also sold three ambulatory surgery centers in South Carolina, resulting in a pre-tax gain of **$43 million**[44](index=44&type=chunk) [NOTE 4. IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION‑RELATED COSTS](index=16&type=section&id=NOTE%204.%20IMPAIRMENT%20AND%20RESTRUCTURING%20CHARGES%2C%20AND%20ACQUISITION%E2%80%91RELATED%20COSTS) This note outlines impairment, restructuring, and acquisition-related costs for the six-month periods ended June 30, 2025 and 2024 Impairment and Restructuring Charges, and Acquisition-Related Costs (Six Months Ended June 30, 2025 vs. 2024) | Charge Type | 6 Months Ended June 30, 2025 ($M) | 6 Months Ended June 30, 2024 ($M) | Change ($M) | Change (%) | | :------------------------------------------ | :-------------------------------- | :-------------------------------- | :---------- | :--------- |

Core Viewpoint - Tenet Healthcare (THC) has experienced a significant decline of 14% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal supported by analyst consensus for better-than-expected earnings [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - THC's current RSI reading is 28.5, suggesting that the heavy selling pressure may be exhausting itself, leading to a potential reversal towards the previous equilibrium of supply and demand [5]. Group 2: Fundamental Analysis - Over the last 30 days, the consensus EPS estimate for THC has increased by 25.3%, indicating a strong agreement among analysts regarding improved earnings for the current year [7]. - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term, further supporting the potential for a rebound in THC's stock price [7]. Group 3: Analyst Ratings - THC holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which is a strong indicator of the stock's potential for a turnaround [8].

Group 1: Edenred SE (EDNMY) - Edenred is a digital platform for services and payments for companies, employees, and merchants [1] - The company has a Zacks Rank of 1 and a Value Score of B [1] - The Zacks Consensus Estimate for its current year earnings has increased by 2.9% over the last 60 days [1] - Edenred has a price-to-earnings ratio (P/E) of 11.12, significantly lower than the industry average of 32.80 [1] Group 2: Tenet Healthcare Corporation (THC) - Tenet Healthcare is a diversified healthcare services company [2] - The company holds a Zacks Rank of 1 and a Value Score of A [2] - The Zacks Consensus Estimate for its current year earnings has increased nearly 3% over the last 60 days [2] - Tenet Healthcare has a price-to-earnings ratio (P/E) of 12.11, compared to 23.85 for the S&P 500 [2] Group 3: Mercantile Bank Corporation (MBWM) - Mercantile Bank is a bank holding company for Mercantile Bank of Michigan [3] - The company carries a Zacks Rank of 1 and a Value Score of B [3] - The Zacks Consensus Estimate for its current year earnings has increased by 2.9% over the last 60 days [3] - Mercantile Bank has a price-to-earnings ratio (P/E) of 9.81, which is lower than the S&P 500 average of 23.85 [3]

Core Viewpoint - Investors in Tenet Healthcare Corporation (THC) should closely monitor the stock due to significant movements in the options market, particularly the Aug 15, 2025 $60 Call, which has shown high implied volatility [1] Group 1: Implied Volatility - Implied volatility indicates the market's expectations for future stock movement, with high levels suggesting anticipation of a significant price change or an upcoming event that could trigger a rally or sell-off [2] - The current high implied volatility for Tenet Healthcare options suggests that traders are expecting a notable price movement [4] Group 2: Analyst Insights - Tenet Healthcare holds a Zacks Rank 3 (Hold) in the Medical – Hospital industry, which is positioned in the top 39% of the Zacks Industry Rank [3] - Over the past 30 days, the Zacks Consensus Estimate for Tenet Healthcare's current quarter earnings has increased from $2.51 per share to $2.64 per share, indicating positive sentiment among analysts [3]

Core Viewpoint - Tenet Healthcare Corporation reported better-than-expected earnings for the second quarter, with significant increases in both earnings per share and sales compared to analyst estimates [1][2]. Financial Performance - The company reported quarterly earnings of $4.02 per share, surpassing the analyst consensus estimate of $2.87 per share [1]. - Quarterly sales reached $5.271 billion, exceeding the analyst consensus estimate of $5.161 billion [1]. Guidance Update - Tenet raised its FY2025 adjusted EPS guidance from a range of $11.99-$13.12 to $15.55-$16.21 [2]. - The sales guidance was also increased from $20.600 billion-$21.000 billion to $20.950 billion-$21.250 billion [2]. Management Commentary - The CEO highlighted strong second quarter results, emphasizing same-store revenue growth, operational performance, and robust free cash flow generation [3]. - The company is focused on both organic and inorganic investments to enhance capabilities and innovate for better patient service [3]. Stock Performance - Following the earnings announcement, Tenet Healthcare shares rose by 1% to trade at $157.49 [3]. Analyst Ratings - Guggenheim analyst Jason Cassorla maintained a Buy rating on Tenet Healthcare and raised the price target from $180 to $188 [6]. - Raymond James analyst John Ransom reiterated an Outperform rating and increased the price target from $185 to $200 [6].

Group 1 - The healthcare sector is experiencing significant downturns in 2025, primarily due to impending large Medicaid cuts [1] - Tenet Healthcare (NYSE: THC) is identified as one of the few positive performers within the struggling healthcare sector [1] Group 2 - The article emphasizes the importance of finding underappreciated companies that can deliver value to investors, aligning with a contrarian investment philosophy [1]

Core Insights - Tenet Healthcare reported strong Q2 2025 earnings, with adjusted EPS of $4.02, significantly exceeding Wall Street expectations of $2.87, and revenue of $5.27 billion, surpassing GAAP forecasts of $5.16 billion [1][5][10] Financial Performance - Adjusted EPS increased by 74% year-over-year from $2.31 to $4.02 [2] - Revenue grew by 3.2% from $5.11 billion in Q2 2024 to $5.27 billion in Q2 2025 [2] - Adjusted EBITDA rose 18.6% to $1.12 billion compared to $945 million in Q2 2024 [2] - Free cash flow reached $743 million, a 23.4% increase from $602 million in Q2 2024 [2][8] Segment Performance - Ambulatory Care segment saw net operating revenue increase by 11.3% to $1.27 billion, with adjusted EBITDA rising 11.4% [6] - Hospital Operations revenue grew modestly by 0.9% to $4.00 billion, with adjusted EBITDA up 25% [7] - Same-hospital admissions increased by 1.6%, while outpatient visits and emergency room visits declined by 3.2% and 4.7%, respectively [7] Strategic Focus - Tenet Healthcare is focused on optimizing its portfolio for growth and profitability, emphasizing the expansion of its outpatient services through United Surgical Partners International (USPI) [3][4] - The company is divesting underperforming hospitals and shifting care to outpatient settings, which are seen as more cost-effective [4] Future Guidance - The company raised its full-year FY2025 guidance, projecting adjusted EBITDA between $4.40 and $4.54 billion and adjusted EPS between $15.55 and $16.21 [10] - Revenue is expected to reach between $20.95 and $21.25 billion, with ambulatory net operating revenues projected between $5.0 and $5.15 billion [10]

Core Insights - Tenet Healthcare Corporation (THC) reported strong second-quarter 2025 results with adjusted earnings per share (EPS) of $4.02, exceeding estimates by 41.6% and showing a year-over-year increase of 74% [1][10] - Net operating revenues rose 3.2% year over year to $5.3 billion, surpassing consensus estimates by 2.4% [1][10] Financial Performance - Adjusted net income for the quarter was $369 million, a 63.3% increase year over year [3] - Adjusted EBITDA improved 18.6% year over year to $1.1 billion, exceeding estimates [3] - Adjusted EBITDA margin increased by 280 basis points to 21.3% [3] Segment Performance - Hospital Operations and Services segment generated net operating revenues of $4 billion, a 0.9% year-over-year increase, beating estimates [5] - Ambulatory Care segment saw net operating revenues rise 11.3% year over year to $1.3 billion, also exceeding estimates [7] Cost and Expenses - Total operating costs increased 2.3% year over year to $4.5 billion, primarily due to higher supplies expenses [4] Cash Flow and Financial Position - Cash and cash equivalents stood at $2.6 billion, down 13.1% from the end of 2024 [9] - Net cash from operations for the first half of 2025 was $1.8 billion, a 31.4% increase year over year [12] Share Repurchase and Guidance - THC repurchased shares worth $747 million in Q2 2025 and increased the share repurchase program by $1.5 billion [13] - The company raised its 2025 adjusted EPS guidance to $15.55-$16.21, indicating a 33.7% rise from the previous year [18]